Retatrutide vs Mounjaro & Zepbound: 24.2% vs 20.9% Weight Loss, Explained

Almost every "retatrutide vs Mounjaro" or "retatrutide vs Zepbound" search hides a second question the searcher hasn't quite asked yet: aren't Mounjaro and Zepbound the same thing? They are. So before the retatrutide comparison makes any sense, the brand names have to be untangled, because comparing retatrutide to "Mounjaro" and "Zepbound" as if they were two rival drugs is comparing it to one drug wearing two labels.

This is written for research and educational purposes. It reports published trial data; it is not medical advice, and retatrutide is a research compound, not an approved medication.

Are Mounjaro and Zepbound the same drug?

Yes, and this is the single most important fact for making sense of any comparison. Mounjaro and Zepbound are both brand names for tirzepatide, the same molecule made by the same manufacturer (Eli Lilly). What differs is the label each brand is approved and marketed under, not the dose. ^{[5] [6]}

This is where the tirzepatide brand pair actually differs from the semaglutide one. Ozempic and Wegovy, the two brand names for semaglutide, are titrated to different maximum doses because Wegovy's label was built specifically to push weight loss further. Mounjaro and Zepbound share the identical 2.5 to 15 mg range. The molecule, the dose ladder, and the pharmacokinetics are the same top to bottom; only the approved use and the name on the box differ. ^{[5] [6]}

Everything below, therefore, is really retatrutide vs tirzepatide, with the Mounjaro/Zepbound naming folded in wherever it changes the practical picture.

Is retatrutide the same as Mounjaro?

No. This is the other half of the confusion, and the answer is cleaner. Mounjaro (and Zepbound) is tirzepatide, a dual agonist that activates two receptors, GIP and GLP-1. Retatrutide (LY3437943) is an investigational triple agonist that activates three receptors, GLP-1, GIP, and glucagon, with a single molecule. ^[3] They are not the same compound, not the same mechanism, and not even the same regulatory status: tirzepatide is FDA-approved, retatrutide is not.

That distinction is the whole reason the numbers diverge. Tirzepatide works two levers; retatrutide works three. Which brings us to the figure everyone actually came for.

Retatrutide vs Mounjaro/Zepbound: the weight-loss numbers

On published mean weight-loss data, retatrutide's figures are the largest reported for this class of compound. Here is the honest side-by-side, remembering that Mounjaro and Zepbound are both tirzepatide.

The headline gap is 24.2% versus 20.9%, and it is a narrower gap than retatrutide's lead over first-generation GLP-1 drugs, which fits the pattern: tirzepatide's dual mechanism already closes part of the distance, and retatrutide's third receptor closes the rest. ^{[1] [2]} The comparison is also the tightest of the brand-pair posts on this site precisely because tirzepatide is the closest mechanistic relative retatrutide has among approved drugs.

Two caveats keep this honest. First, these are separate trials, with different participants, durations, and designs, not a head-to-head study, so the percentages can't be treated as if they came from the same experiment. Second, "Mounjaro" and "Zepbound" are the same tirzepatide; if you see a chart pitting all three against each other as distinct drugs, it's built on a misunderstanding. The head-to-head that actually exists in the literature is retatrutide's mechanism-driven lead over the dual-receptor compound behind both brands. For the deeper mechanism breakdown behind that pairing, including full dosing, side-effect, and cost detail, see retatrutide vs tirzepatide.

Why retatrutide's number is bigger: mechanism

The efficacy gap isn't a formulation trick. It's receptor coverage. Tirzepatide, the drug in Mounjaro and Zepbound, is a dual agonist: it activates GLP-1 and GIP together, driving appetite suppression, slowed gastric emptying, and improved glucose handling. Those two levers are enough to reach 20.9% at the SURMOUNT-1 top dose. ^[2]

Retatrutide keeps both of those levers and adds a third. ^[3]

GIP appears to amplify GLP-1's effects rather than act alone, which is widely thought to be why tirzepatide's dual agonism already outperformed single-receptor GLP-1 drugs like semaglutide. ^[3] Glucagon is retatrutide's genuinely novel addition on top of that: on its own it raises blood glucose, but paired with strong incretin coverage its contribution, energy expenditure and lipid mobilization, is retained while the incretin arms offset the glycemic penalty. In plain terms, tirzepatide already works both the intake side and part of the amplification side of energy balance, while retatrutide adds a third lever on the output side. That is the mechanistic reason the trial numbers separate, even by a narrower margin than the first-generation comparisons.

Do retatrutide, Mounjaro, and Zepbound have the same side effects?

The tolerability story is more alike than different, because all three lean on the same GLP-1/GIP foundation. Both compounds are dominated by dose-dependent gastrointestinal effects, including nausea, diarrhea, constipation, and reduced appetite, that cluster during dose escalation and then ease at a stable dose. ^{[1] [2]} This is the incretin-class signature, and it is why both tirzepatide and retatrutide are titrated gradually rather than started at the target dose.

Because Mounjaro and Zepbound are the same molecule at the same dose range, their side-effect profiles are identical in both type and typical intensity, unlike the Ozempic/Wegovy pair where the higher-dosed brand tends to surface effects more often. With tirzepatide, whichever label is prescribed, the dose drives the intensity, not the brand.

The one notable difference from retatrutide's data is a skin-sensation effect, dysesthesia, meaning tingling or altered sensation, reported at higher doses in its Phase 2 trial, which is not a prominent feature of tirzepatide's profile. ^[1] Trials also report a modest heart-rate increase for both compounds. As with every figure here, these are trial-reported findings describing study populations, not predictions for any individual.

Why the GI effects happen and why they fade

The nausea isn't incidental; it's a direct extension of the mechanism shared by all three. GLP-1 activation slows gastric emptying, which is part of how these compounds reduce appetite, and that same slowing is what produces nausea when it changes too abruptly. That is why effects are worst during dose escalation, when exposure is moving fastest, and why they settle once the dose and plasma level stabilize. The stepwise titration schedule exists precisely to give the system time to adapt at each level. ^{[1] [2]}

Dosing cadence: how retatrutide, Mounjaro, and Zepbound compare

Here the three are close in shape, closer than the semaglutide brand pair. All are once-weekly subcutaneous compounds with multi-day half-lives (retatrutide about 6 days, tirzepatide about 5 days) ^[4], which is exactly what makes weekly dosing viable and means all of them take about a month of accumulation to reach steady state. All use gradual dose titration.

The doses look different, up to 12 mg versus up to 15 mg, but that's a comparison of two different molecules, not two different potencies of the same one. Milligram-for-milligram numbers across different peptides mean little; what matters is the effect each reaches at its own studied dose. Where Mounjaro and Zepbound don't differ at all is the ladder itself: both climb through the identical 2.5 to 15 mg schedule, since they are literally the same drug approved for two indications.

If you understand one compound's weekly cadence, you understand all three. The pharmacokinetics that drive the roughly 6-day retatrutide half-life, including the roughly month-long ramp to steady state, are covered in the complete retatrutide guide.

What the response rates showed

Averages hide variation, so the sharper question is how consistently each worked. Tirzepatide's SURMOUNT-1 trial reported that a large majority of participants at the 15 mg dose crossed meaningful thresholds: roughly 96% reached at least 5% loss, about 90% reached 10%, and about 78% reached 15%. ^[2] Retatrutide's Phase 2 data reported a higher-responding distribution at the top doses, with essentially all participants reaching at least 5% loss and a large majority reaching 15% or more. ^[1]

The practical read is that both are reliable in the sense that most subjects respond; they differ in how far that response goes. That is the same conclusion the mechanism predicts: two levers versus three.

Availability: brand-name prescription vs research compound

This is where the comparison stops being about biology and becomes about how you'd actually obtain each, which is the difference the trial numbers can't tell you.

Mounjaro and Zepbound are FDA-approved prescription drugs. They are prescribed by a licensed clinician, dispensed by a pharmacy, and manufactured to pharmaceutical standards. Their identity and purity are not something a buyer has to verify, since that's what approval and pharmacy dispensing guarantee. What you trade for that certainty is access friction: prescriptions, insurance, and, at various points, supply shortages that have affected both brands.

Retatrutide is investigational and not approved for human use. It is available only through the research-compound market, which means sourcing quality becomes the decisive variable: the role the pharmacy and the FDA play for tirzepatide falls to you and your supplier. The single most important thing to verify is a batch-matched certificate of analysis tied to a specific lot: mass by HPLC, identity by mass spectrometry, a measured purity figure, and a characterized impurity profile, ideally confirmed by independent third-party testing rather than the manufacturer's own numbers alone.

Modern Bio's retatrutide ships with a batch-matched COA on every vial, the closest a research compound comes to the identity assurance an approved prescription provides by default.

Why retatrutide is better than Mounjaro: the honest version

It's a common search, so it deserves a precise answer rather than a slogan. On the evidence:

• On mean weight loss, retatrutide's trial figures are larger: 24.2% vs 20.9%, at a shorter measurement window. ^{[1] [2]}
• On mechanism, retatrutide is more comprehensive, with three complementary receptors versus two. ^[3]
• On maturity and access, tirzepatide (Mounjaro/Zepbound) is clearly ahead, with a large SURMOUNT and SURPASS trial program, regulatory approval, and pharmacy dispensing that a research compound cannot match.

So "better" depends entirely on the axis. For peak studied efficacy and the newest mechanism, retatrutide leads. For an established, approved, extensively characterized dual-receptor reference, tirzepatide, under either brand, is the standard. A credible comparison names the axis instead of declaring a universal winner. And retatrutide is not the only compound in this conversation: the single-receptor GLP-1 drugs semaglutide, sold as Ozempic and Wegovy, sit further behind on mean weight loss, covered in retatrutide vs Ozempic & Wegovy.

Which one suits which research question

Tirzepatide is the established dual-receptor reference, with the deepest characterization and the longest track record among next-generation incretin drugs, which is exactly why it's the drug behind both Mounjaro and Zepbound. Retatrutide is the efficacy frontier, the newest mechanism and the largest trial effect, the compound to study when the question is about maximal response. Many research programs study both precisely to map the gap between two levers and three.

The bottom line

Mounjaro and Zepbound are one drug, tirzepatide, under two labels, sharing the same 2.5 to 15 mg dosing range and separated only by approved use. Retatrutide is a different molecule and a different mechanism: a triple agonist whose Phase 2 data (24.2%) run ahead of tirzepatide's SURMOUNT-1 figure (20.9%), from separate trials, for reasons the receptor coverage predicts. ^{[1] [2] [3]} The trade is maturity and access: the brands are approved and pharmacy-dispensed, while retatrutide is a research compound where a batch-matched COA does the verification a prescription otherwise would. For the full evidence base on retatrutide itself, start with the complete retatrutide guide.

For research and educational purposes only. Not medical advice. Mounjaro and Zepbound are FDA-approved prescription medications referenced here for comparison; retatrutide is investigational and is not approved for human use. Cross-compound figures are drawn from separate clinical trials, not head-to-head studies.